Jhaveri, Komal

Publications

Sort by

Co-Author Network

selected publications

Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted ⁸⁹Zr-Pertuzumab PET/CT. Radiology. 2020 Academic Article GET IT
Times cited: 42
Characterization of on-target adverse events caused by TRK inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2020 Academic Article GET IT
Times cited: 43
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors. Science (New York, N.Y.). 2019 Academic Article GET IT
Times cited: 192
Paradigms for Precision Medicine in Epichaperome Cancer Therapy. Cancer cell. 2019 Academic Article GET IT
Times cited: 44
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer cell. 2018 Academic Article GET IT
Times cited: 636
Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 23
A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER⁺/HER2^- Advanced Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 43
HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018 Academic Article GET IT
Times cited: 588
First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using ⁸⁹Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017 Academic Article GET IT
Times cited: 132
Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer. Breast cancer research and treatment. 2017 Academic Article GET IT
Times cited: 11
A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer. Breast cancer research : BCR. 2017 Academic Article GET IT
Times cited: 49
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. Investigational new drugs. 2017 Academic Article GET IT
Times cited: 12
Voxelwise analysis of simultaneously acquired and spatially correlated ¹⁸ F-fluorodeoxyglucose (FDG)-PET and intravoxel incoherent motion metrics in breast cancer. Magnetic resonance in medicine. 2016 Academic Article GET IT
Times cited: 10
Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer. Radiology. 2016 Academic Article GET IT
Times cited: 109
Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy. Clinical breast cancer. 2015 Academic Article GET IT
Times cited: 51
Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors. Clinical breast cancer. 2015 Academic Article GET IT
Times cited: 10
Ganetespib: research and clinical development. OncoTargets and therapy. 2015 Information Resource GET IT
Times cited: 82
Predictive Value of Positron Emission Tomography/Computed Tomography to Assess Early Treatment Response to Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade Without Chemotherapy for HER2-Positive Metastatic Breast Cancer: Are We Ready to Embrace This "Early Metabolic Look" Strategy?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Editorial Article GET IT
Times cited: 1
A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget. 2015 Academic Article GET IT
Times cited: 22
HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. British journal of cancer. 2014 Information Resource GET IT
Times cited: 96
Pertuzumab in the treatment of HER2+ breast cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2014 Information Resource GET IT
Times cited: 15
Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast cancer research : BCR. 2014 Academic Article GET IT
Times cited: 72
Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. Expert opinion on investigational drugs. 2014 Information Resource GET IT
Times cited: 139
A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clinical breast cancer. 2013 Academic Article GET IT
Times cited: 69
Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer. Cancer medicine. 2013 Academic Article GET IT
Times cited: 50
Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature. Breast cancer research and treatment. 2013 Information Resource GET IT
Times cited: 16
Hepatic arterial infusion and systemic chemotherapy for breast cancer liver metastases. The breast journal. 2012 Academic Article GET IT
Times cited: 8
Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. Cancer. 2012 Academic Article GET IT
Times cited: 34
A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 46
HSP90 inhibitors for cancer therapy and overcoming drug resistance. Advances in pharmacology (San Diego, Calif.). 2012 Article GET IT
Times cited: 59
Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochimica et biophysica acta. 2011 Information Resource GET IT
Times cited: 408
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma. 2007 GET IT
Times cited: 21
ICMR task force study on hormonal contraception. Transfer of levonorgestrel (LNG) administered through different drug delivery systems from the maternal circulation into the newborn infant's circulation via breast milk. Contraception. 1987 Academic Article GET IT
Times cited: 22

more ...

less ...

Background

education and training

M.B.,B.S., K.J. Somaiya Medical College (India) 2001
B.S., Mumbai University (India) 1995

Contact

full name

Komal Jhaveri

VIVO Weill Cornell Medical College

Komal Jhaveri Associate Professor of Clinical Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name